Chinese | English

  • Home
  • Service
    • FEASIBILITY STUDY
    • BE/PK/PD/PHASE I
    • PHASE II-IV/IIS/PMS
    • SUBJECT RECRUITMENT
    • SAS/STATISTICS ANALYSIS
    • MEDICAL WRITING/MONITOR
    • 3rd PARTY QA AUDIT
    • STAFF OUTSOURCING
    • EDC/DATABASE/DATA MANAGEMENT
    • REGULATORY AFFAIRS
    • MEDICAL BIGDATA & RWS
    • PHARMACOVIGILANCE
    • MARKETING RESEARCH/ACCESS
  • Client&feedback
    • OUR CLIENTS

    • CLIENTS'RECOGNITION

    • CASE STUDY

    • CLIENTS'FEEDBACK

    • PROJECTS COMPLETED

  • NEWS CENTER
    • COMPANY NEWS
    • PHOTOGRAPHY NEWS
  • Listing information
  • About us
    • ABOUT COMPANY
    • Management team
    • Corporate Advantages
    • DEVELOPMENT HISTORY
    • Video data

    • Contact us

News

  • COMPANY NEWS

  • PHOTOGRAPHY NEWS

Your current location:Home > News
  • Clinical trends of A class new drugs in China in December 20182019-01-15
  • H&J carried out the activity "sweeping the dust to welcome the new"2019-01-14
  • Stick to the first line2019-01-11
  • H&J HR department interpret the new policy of personal income tax2019-01-09
  • Shiyao Group visits Yanjiao data center2019-01-09
  • Data management department 2019 annual meeting2019-01-07
  • Overcoming the difficulties, H&J has done the arduous task beautifully.2019-01-03
  • New Year's Message from Prof. MENG2019-01-02
  • Our company and Henan University of Science and Technology signed the cooperation agreement between school and enterpris2018-12-29
  • The leaders of H&J met Wuhan United pharmaceutical customers2018-12-24
  • Seminar on The Medical Big-Data Application2018-12-24
  • Potential French Partner visited H&J Beijing Office2018-12-24
  • H&J signed a teaching cooperation agreement with Taishan Medical University2018-12-24
  • Sponsor: working hard with H&J2018-12-24
上一页 12345 下一页
Han Bo Rui Qiang (Shanghai) Pharma-Tech Ltd,?H&J CRO International--New York LLC? ?Copyright H&J 2019